Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
6Customers
3Debt Items
7Related Chains
Source-Backed Evidence Depth
Larimar Therapeutics, Inc. (LRMR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
6High confidence
0.758Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Larimar Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
INDIANA-UNIVERSITY
INDIANA-UNIVERSITY
92%
The Company is obligated to pay IU certain milestone payments of up to $ 2.0 million in the aggregate upon the achievement of certain developmental milestones
WAKE-FOREST-UNIVERSITY-HEALTH-SCIENCES
WAKE-FOREST-UNIVERSITY-HEALTH-SCIENCES
80%
We were previously a party to the License Agreement dated November 30, 2016, with Wake Forest University Health Sciences
Reciprocal relationship from LXEO graph: Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO g…
Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso…
CHONDRIAL-THERAPEUTICS-HOLDINGS-LLC
CHONDRIAL-THERAPEUTICS-HOLDINGS-LLC
62%
e FDA ultimately will grant traditional approval or that the accelerated approval will not be withdrawn. • Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities…
CHONDRIAL-THERAPEUTICS-INC
CHONDRIAL-THERAPEUTICS-INC
62%
e FDA ultimately will grant traditional approval or that the accelerated approval will not be withdrawn. • Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities…
KBI-BIOPHARMA-INC
KBI-BIOPHARMA-INC
62%
e FDA ultimately will grant traditional approval or that the accelerated approval will not be withdrawn. • Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities…
ZAFGEN-ZORDICH-MERGER-SUB-INC
ZAFGEN-ZORDICH-MERGER-SUB-INC
62%
e FDA ultimately will grant traditional approval or that the accelerated approval will not be withdrawn. • Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities…
ZORDICH-MERGER-SUB-INC
ZORDICH-MERGER-SUB-INC
62%
e FDA ultimately will grant traditional approval or that the accelerated approval will not be withdrawn. • Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities…
Larimar Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
LRMR-DEBT
Debt stack $14.5M
90%
Market cache reports total debt of $14.5M.
LRMR-DEBT-10797
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2012-12-31.
LRMR-DEBT-10796
Warrants outstanding: 628403
90%
xbrl warrant detail from xbrl 2023-08-11.
Larimar Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Larimar Therapeutics, Inc..
Larimar Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
LRMR-OWNER-DEERFIELD-MANAGEMENT-COMPANY-L-P
DEERFIELD MANAGEMENT COMPANY, L.P.
90%
13F overlay lists DEERFIELD MANAGEMENT COMPANY, L.P. as top holder; 163 tracked holders.
Larimar Therapeutics, Inc. Extended Supply Chain Network
